Sarepta Therapeutics (SRPT) Tops Q2 EPS by 57c, provides guidance

Sarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of $0.44, $0.57 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $362.9 million versus the consensus estimate of $394.39 million.

GUIDANCE:

Sarepta Therapeutics sees FY2025 revenue of $2.9-3.1 billion, versus the consensus of $3.241 billion.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• HASI makes first water infrastructure investment in Washington State